Opinion

Video

Future of BCG in NMIBC

Author(s):

Mark D. Tyson, MD, MPH,Gary D. Steinberg, MD

Panelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the future of first-line treatment be a noninfectious agent that would be easier to develop and include more data.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Given these recent advances and emerging agents, do you think BCG monotherapy will remain the first-line treatment for intermediate-risk and high-risk disease?
      Related Videos
      Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
      Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
      Final Thoughts and Clinical Trials in NMIBC
      Final Thoughts and Clinical Trials in NMIBC
      Uptake of New Treatments in Urology Practice
      Uptake of New Treatments in Urology Practice
      Patient Communication and Treatment Adherence in NMIBC
      Patient Communication and Treatment Adherence in NMIBC
      Urinary bladder | Image Credit: © magicmine - stock.adobe.com
      Expert describes implications of neoadjuvant durvalumab approval in MIBC
      Sima Porten, MD, on gene-environment interactions in bladder cancer development
      Sima Porten, MD, on gene-environment interactions in bladder cancer development
      1 expert in this video
      Resective Surgery and Minimally Invasive Procedures For BPH
      3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      How rBCG EAP could open up access for Anktiva in bladder cancer
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Operationalizing TAR-200 and Other Delivery Systems in Practice
      Operationalizing TAR-200 and Other Delivery Systems in Practice
      Related Content
      3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      April 17th 2025

      NMIBC Clinical Forums highlight novel therapies and treatment strategies

      Urology Times staff
      Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.
      Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
      January 14th 2025

      Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

      Wayne Kuang, MD Steven Maislos, MD
      Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
      FDA approval sought for Anktiva in papillary NMIBC
      April 15th 2025

      FDA approval sought for Anktiva in papillary NMIBC

      Hannah Clarke
      The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.
      Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
      November 27th 2024

      Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

      Wayne Kuang, MD Bilal Chughtai, MD
      Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
      Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
      April 2nd 2025

      The importance of federal funding in cancer research: A call to action

      Michael S. Cookson, MD, MMHC
      "We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
      FDA updates in urology: March 2025
      April 1st 2025

      FDA updates in urology: March 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from March 2025.
      © 2025 MJH Life Sciences

      All rights reserved.